4 results
What is the prevalence of gastro-intestinal disorders and which are the determinants?
Primary Objective:To demonstrate that CHF 1535 twice daily is superior to Formoterol twice daily in terms of COPD exacerbations rate during 48 weeks of treatment and in terms of pulmonary function (change in pre-dose morning FEV1 from baseline to 12…
To evaluate the long-term safety and tolerability of elsubrutinib and upadacitinib given alone or as the ABBV-599 (elsubrutinib/upadacitinib) combination in SLE subjects who have completed the M19-130 Phase 2 study.
The aim of this study will be to evaluate the applicability of using CCE in the Dutch colorectal cancer screening programme in participants with positive FIT outcomes who have contra-indications for subsequent colonoscopy, who have a prior…